Obesity and inflammation: Epidemiology, risk factors, and markers of inflammation

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Rodríguez Hernández, Heriberto ^a   Simental Mendía, Luis E ^a   Rodríguez Ramírez, Gabriela ^a   Reyes Romero, Miguel A ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DIET THERAPY; EPIDEMIC; HUMAN; INFLAMMATION; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84877266773     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/678159     Document Type: Review

References (187)

1. Finucane M. M., Stevens G. A., Cowan M. J., Danaei G., Lin J. K., Paciorek C. J., Singh G. M., Gutierrez H. R., Lu Y., Bahalim A. N., Farzadfar F., Riley L. M., Ezzati M., National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. The Lancet 2011 377 9765 557 567 2-s2.0-79951558318 10.1016/S0140-6736(10)62037-5
2. Ford E. S., Mokdad A. H., Epidemiology of obesity in the Western Hemisphere. The Journal of Clinical Endocrinology and Metabolism 2008 93 S1 S8
3. National Institutes of Health, Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults 1998 Bethesda, Md, USA U.S. Department of Health and Human Services
4. Kuczmarski R. J., Flegal K. M., Campbell S. M., Johnson C. L., Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. Journal of the American Medical Association 1994 272 3 205 211 2-s2.0-0028322089 10.1001/jama.272.3.205 (Pubitemid 24209082)
5. Troiano R. P., Flegal K. M., Kuczmarski R. J., Campbell S. M., Johnson C. L., Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Surveys, 1963 to 1991. Archives of Pediatrics and Adolescent Medicine 1995 149 10 1085 1091 2-s2.0-0028889807
6. Freedman D. S., Khan L. K., Serdula M. K., Galuska D. A., Dietz W. H., Trends and correlates of class 3 obesity in the United States from 1990 through 2000. Journal of the American Medical Association 2002 288 14 1758 1761 2-s2.0-0037048640
7. Orpana H. M., Berthelot J. M., Kaplan M. S., Feeny D. H., McFarland B., Ross N. A., BMI and mortality: results from a national longitudinal study of canadian adults. Obesity 2009 18 1 214 218 2-s2.0-73949159543 10.1038/oby.2009.191
8. Hotamisligil G. S., Inflammation and metabolic disorders. Nature 2006 444 7121 860 867 2-s2.0-33845866857 10.1038/nature05485 (Pubitemid 46024993)
9. Ridker P. M., Buring J. E., Shih J., Matias M., Hennekens C. H., Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998 98 8 731 733 2-s2.0-0032566401 (Pubitemid 28391836)
10. Kaplan M. S., Huguet N., Newsom J. T., McFarland B. H., Lindsay J., Prevalence and correlates of overweight and obesity among older adults: findings from the Canadian National Population Health Survey. Journals of Gerontology A 2003 58 11 1018 1030 2-s2.0-0345447504 (Pubitemid 37467300)
11. Adams L. A., Lymp J. F., Sauver J. S., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P., The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129 1 113 121 2-s2.0-22344452893 10.1053/j.gastro.2005.04.014 (Pubitemid 41002048)
12. Angulo P., Medical progress: nonalcoholic fatty liver disease. The New England Journal of Medicine 2002 346 16 1221 1231 2-s2.0-0037129380 10.1056/NEJMra011775 (Pubitemid 34984585)
13. Bellentani S., Marino M., Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology 2009 8 supplement 1 S4 S8 2-s2.0-66749106254
14. Ruhl C. E., Everhart J. E., Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology 2010 138 4 1346.e3 1356.e3 2-s2.0-77949840241 10.1053/j.gastro.2009.12.053
15. Rodriguez-Hernandez H., Cervantes-Alvarez M., Rodriguez- Moran M., Guerrero-Romero F., Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Annals of Hepatology 2011 10 486 492
16. Rodriguez-Hernandez H., Morales-Amaya U. A., Rosales-Valdéz R., Rivera-Hinojosa F., Rodriguez-Moran M., Guerrero-Romero F., Adding cognitive behavioural treatment to either low-carbohydrate or low-fat diets: differential short-term effects. British Journal of Nutrition 2009 102 12 1847 1853 2-s2.0-74949099520 10.1017/S0007114509991231
17. Stepanova M., Younoussi Z. M., Independent association between nonalcoholic fatty liver disease and cardiovascular disease in US population. Clinical Gastroenterology and Hepatology 2012 10 646 650
18. Kuper H., Tzonou A., Kakalamani E., Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocelular carcinoma. International Journal of Cancer 2000 85 498 502 (Pubitemid 30075127)
19. Trichopoulos D., Bamia C., Lagiou P., Hepatocelular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. Journal of the National Cancer Institute 2011 103 1686 1695
20. Freedman N. D., Marrero J. A., Can dietary fish intake prevent liver cancer? Gastroenterology 2012 142 1411 1413
21. Su L. J., Mahabir S., Ellison G. L., McGuinn L. A., Reid B. C., Epigenetic contributions to the relationship between cancer and dietary intake of nutrients, bioactive food, components, and environmental toxicants. Nutrigenomics 2012 2 1 12
22. Gregor M. F., Hotamisligil G. S., Inflammatory mechanisms in obesity. Annual Review of Immunology 2011 29 415 445
23. Faloia E., Michetti G., de Robertis M., Luconi M. P., Furlani G., Boscaro M., Inflammation as a link between obesity and metabolic syndrome. Journal of Nutrition and Metabolism 2012 2012 7 476380 10.1155/2012/476380
24. Stienstra R., Tack C. J., Kanneganti T. D., Joosten L. A., Netea M. G., The inflammasome puts obesity in the danger zone. Cell Metabolism 2012 15 10 18
25. Solinas G., Karin M., JNK1 and IKK β: molecular links between obesity and metabolic dysfunction. The FASEB Journal 2010 24 8 2596 2611 2-s2.0-77955806634 10.1096/fj.09-151340
26. Boura-Halfon S., Zick Y., Phosphorylation of IRS proteins, insulin action, and insulin resistance. American Journal of Physiology 2009 296 4 E581 E591 2-s2.0-65649098029 10.1152/ajpendo.90437.2008
27. Schroder K., Zhou R., Tschopp J., The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010 327 5963 296 300 2-s2.0-74549184092 10.1126/science.1184003
28. Shi H., Kokoeva M. V., Inouye K., Tzameli I., Yin H., Flier J. S., TLR4 links innate immunity and fatty acid-induced insulin resistance. The Journal of Clinical Investigation 2006 116 11 3015 3025 2-s2.0-33750584214 10.1172/JCI28898 (Pubitemid 44684486)
29. Lamkanfi M., Kanneganti T. D., The inflammasome: a remote control for metabolic syndrome. Cell Research 2012 22 1095 1098
30. Church L. D., Cook G. P., McDermott M. F., Primer: inflammasomes and interleukin 1 β in inflammatory disorders. Nature Clinical Practice Rheumatology 2008 4 1 34 42 2-s2.0-38049083888 10.1038/ncprheum0681
31. Dagenais M., Dupaul-Chicoine J., Saleh M., Function of NOD-like receptors in immunity and disease. Current Opinion in Investigational Drugs 2010 11 11 1246 1255 2-s2.0-78650340744
32. Dagenais M., Skeldon A., Saleh M., The inflammasome: in memory of Dr. Jurg Tschopp. Cell Death and Differentiation 2012 19 5 12
33. Vandanmagsar B., Youm Y. H., Ravussin A., Galgani J. E., Stadler K., Mynatt R. L., Ravussin E., Stephens J. M., Dixit V. D., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Cell Death and Differentiation 2011 17 179 188
34. Larsen C. M., Faulenbach M., Vaag A., Vølund A., Ehses J. A., Seifert B., Mandrup-Poulsen T., Donath M. Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine 2007 356 15 1517 1526 2-s2.0-34247170807 10.1056/NEJMoa065213 (Pubitemid 46588416)
35. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology 2010 11 2 136 140 2-s2.0-75649096002 10.1038/ni.1831
36. Hotamisligil G. S., Peraldi P., Budavari A., Ellis R., White M. F., Spiegelman B. M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α-and obesity-induced insulin resistance. Science 1996 271 5249 665 668 2-s2.0-0030061922 (Pubitemid 26052915)
37. Wang B., Trayhurn P., Acute and prolonged effects of TNF- α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Archiv European Journal of Physiology 2006 452 4 418 427 2-s2.0-33745511212 10.1007/s00424-006-0055-8 (Pubitemid 43962051)
38. Stenlöf K., Wernstedt I., Fjällman T., Wallenius V., Wallenius K., Jansson J. O., Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 9 4379 4383 2-s2.0-0141675985 10.1210/jc.2002-021733 (Pubitemid 37153746)
39. Naugler W. E., Karin M., The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends in Molecular Medicine 2008 14 3 109 119 2-s2.0-40649109728 10.1016/j.molmed.2007.12.007
40. Pickup J. C., Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004 27 3 813 823 2-s2.0-1442275317 10.2337/diacare.27.3.813 (Pubitemid 38280558)
41. Baumann H., Gauldie J., The acute phase response. Immunology Today 1994 15 2 74 80 2-s2.0-0028095919 10.1016/0167-5699(94)90137-6 (Pubitemid 24049800)
42. Gabay C., Kushner I., Acute-phase proteins and other systemic responses to inflammation. The New England Journal of Medicine 1999 340 6 448 454 2-s2.0-0033545342 10.1056/NEJM199902113400607 (Pubitemid 29084777)
43. Yudkin J. S., Kumari M., Humphries S. E., Mohamed-Ali V., Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000 148 2 209 214 2-s2.0-0033984744 10.1016/S0021-9150(99) 00463-3 (Pubitemid 30064452)
44. Yudkin J. S., Adipose tissue, insulin action and vascular disease: inflammatory signals. International Journal of Obesity 2003 27 supplement 3 S25 S28 2-s2.0-0346250163 10.1038/sj.ijo.0802346 (Pubitemid 38019184)
45. Pearson T. A., Mensah G. A., Alexander R. W., Anderson J. L., Cannon R. O., Criqui M., Fadl Y. Y., Fortmann S. P., Hong Y., Myers G. L., Rifai N., Smith S. C., Taubert K., Tracy R. P., Vinicor F., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003 107 3 499 511 2-s2.0-0037469232 10.1161/01.CIR.0000052939.59093.45 (Pubitemid 36158056)
46. Pepys M. B., Hirschfield G. M., C-reactive protein: a critical update. The Journal of Clinical Investigation 2003 111 12 1805 1812 2-s2.0-0042744797 10.1172/JCI200318921 (Pubitemid 38057722)
47. Jacobs M., van Greevenbroek M. M. J., van der Kallen C. J. H., Ferreira I., Blaak E. E., Feskens E. J. M., Jansen E. H. J. M., Schalkwijk C. G., Stehouwer C. D. A., Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. European Journal of Clinical Investigation 2009 39 6 437 444 2-s2.0-65549153242 10.1111/j.1365-2362.2009. 02129.x
48. Kern P. A., Saghizadeh M., Ong J. M., Bosch R. J., Deem R., Simsolo R. B., The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. The Journal of Clinical Investigation 1995 95 5 2111 2119 2-s2.0-0028968879
49. Lapice E., Maione S., Patti L., Cipriano P., Rivellese A. A., Riccardi G., Vaccaro O., Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care 2009 32 9 1734 1736 2-s2.0-69549105884 10.2337/dc09-0176
50. Laaksonen D. E., Niskanen L., Nyyssönen K., Punnonen K., Tuomainen T. P., Valkonen V. P., Salonen R., Salonen J. T., C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004 47 8 1402 1410 2-s2.0-16644382305 10.1007/s00125-004-1472-x (Pubitemid 39232426)
51. Feingold K. R., Grunfeld C., Role of cytokines in inducing hyperlipidemia. Diabetes 1992 41 supplement 2 97 101 2-s2.0-0026660277
52. Hotamisligil G. S., Spiegelman B. M., Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994 43 11 1271 1278 2-s2.0-0028587742
53. Pi-Sunyer F. X., The obesity epidemic: pathophysiology and consequences of obesity. Obesity Research 2002 10 supplement 10 97S 104S 2-s2.0-0042484813 (Pubitemid 41132563)
54. Caballero A. E., Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obesity Research 2003 11 11 1278 1289 2-s2.0-1542545604 (Pubitemid 41127348)
55. Berg A. H., Scherer P. E., Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005 96 9 939 949 2-s2.0-19044393872 10.1161/01.RES.0000163635.62927.34 (Pubitemid 40712793)
56. Lau D. C. W., Dhillon B., Yan H., Szmitko P. E., Verma S., Adipokines: molecular links between obesity and atheroslcerosis. American Journal of Physiology 2005 288 5 H2031 H2041 2-s2.0-18044366410 10.1152/ajpheart.01058.2004 (Pubitemid 40604084)
57. Visser M., Bouter L. M., McQuillan G. M., Wener M. H., Harris T. B., Low-grade systemic inflammation in overweight children. Pediatrics 2001 107 1 1 6 2-s2.0-0035234153
58. Nicoletti G., Giugliano G., Pontillo A., Cioffi M., D'Andrea F., Giugliano D., Esposito K., Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. Journal of Endocrinological Investigation 2003 26 3 RC5 RC8 2-s2.0-0038543054 (Pubitemid 36681735)
59. Heilbronn L. K., Noakes M., Clifton P. M., Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 6 968 970 2-s2.0-0035716609 (Pubitemid 34168654)
60. Kopp H. P., Kopp C. W., Festa A., Krzyzanowska K., Kriwanek S., Minar E., Roka R., Schernthaner G., Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 6 1042 1047 2-s2.0-0038120873 10.1161/01.ATV.0000073313.16135.21 (Pubitemid 36713558)
61. Reaven G. M., Role of insulin resistance in human disease. Diabetes 1988 37 12 1595 1607 2-s2.0-0024160877 (Pubitemid 19004941)
62. Ferrannini E., Haffner S. M., Mitchell B. D., Stern M. P., Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia 1991 34 6 416 422 2-s2.0-0025780331
63. Gray R. S., Fabsitz R. R., Cowan L. D., Lee E. T., Howard B. V., Savage P. J., Risk factor clustering in the insulin resistance syndrome. The strong heart study. American Journal of Epidemiology 1998 148 9 869 878 2-s2.0-3543110722 (Pubitemid 28484106)
64. Carantoni M., Zuliani G., Volpato S., Palmieri E., Mezzetti A., Vergnani L., Fellin R., Relationships between fasting plasma insulin, anthropometrics, and metabolic parameters in a very old healthy population. Metabolism 1998 47 5 535 540 2-s2.0-0031943394 10.1016/S0026-0495(98)90236-0 (Pubitemid 28213113)
65. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
66. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D. R., Miles J. M., Yudkin J. S., Klein S., Coppack S. W., Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor- α in vivo. Journal of Clinical Endocrinology and Metabolism 1997 82 12 4196 4200 2-s2.0-0030735542 (Pubitemid 27525539)
67. Anty R., Bekri S., Luciani N., Saint-Paul M. C., Dahman M., Iannelli A., Amor I. B., Staccini-Myx A., Huet P. M., Gugenheim J., Sadoul J. L., Le Marchand-Brustel Y., Tran A., Gual P., The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. American Journal of Gastroenterology 2006 101 8 1824 1833 2-s2.0-33746703237 10.1111/j.1572-0241.2006.00724.x (Pubitemid 44166593)
68. Calabro P., Chang D. W., Willerson J. T., Yeh E. T. H., Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. Journal of the American College of Cardiology 2005 46 6 1112 1113 2-s2.0-24944454234 10.1016/j.jacc.2005.06.017 (Pubitemid 41316523)
69. Florez H., Castillo-Florez S., Mendez A., Casanova-Romero P., Larreal-Urdaneta C., Lee D., Goldberg R., C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Research and Clinical Practice 2006 71 1 92 100 2-s2.0-29244447134 10.1016/j.diabres.2005.05.003 (Pubitemid 41821148)
70. González A. S., Guerrero D. B., Soto M. B., Díaz S. P., Martinez-Olmos M., Vidal O., Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. European Journal of Clinical Nutrition 2006 60 6 802 809 2-s2.0-33744927645 10.1038/sj.ejcn.1602384 (Pubitemid 43842236)
71. Ouchi N., Kihara S., Funahashi T., Nakamura T., Nishida M., Kumada M., Okamoto Y., Ohashi K., Nagaretani H., Kishida K., Nishizawa H., Maeda N., Kobayashi H., Hiraoka H., Matsuzawa Y., Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003 107 5 671 674 2-s2.0-0037432152 10.1161/01.CIR.0000055188.83694.B3 (Pubitemid 36222590)
72. van Guilder G. P., Hoetzer G. L., Greiner J. J., Stauffer B. L., DeSouza C. A., Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity 2006 14 12 2127 2131 2-s2.0-33846308173 10.1038/oby.2006.248 (Pubitemid 46121966)
73. Ingelsson E., Hulthe J., Lind L., Inflammatory markers in relation to insulin resistance and the metabolic syndrome. European Journal of Clinical Investigation 2008 38 7 502 509 2-s2.0-45149115075 10.1111/j.1365-2362.2008. 01962.x (Pubitemid 351832033)
74. Matsuo Y., Hashizume T., Shioji S., Akasaka T., Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease. Circulation Journal 2008 72 12 2046 2050 2-s2.0-56849087900 10.1253/circj.CJ-08-0337
75. Kressel G., Trunz B., Bub A., Hülsmann O., Wolters M., Lichtinghagen R., Stichtenoth D. O., Hahn A., Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis 2009 202 1 263 271 2-s2.0-57649217610 10.1016/j.atherosclerosis.2008.04.012
76. Bataille R., Klein B., Kushner I., C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis and Rheumatism 1992 35 8 982 984 2-s2.0-0026642471 10.1002/art.1780350824
77. Heinrich P. C., Castell J. V., Andus T., Interleukin-6 and the acute phase response. Biochemical Journal 1990 265 3 621 636 2-s2.0-0025190892 (Pubitemid 20053863)
78. Castell J. V., Gomez-Lechon M. J., David M., Andus T., Geiger T., Trullenque R., Fabra R., Heinrich P. C., Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Letters 1989 242 2 237 239 2-s2.0-0024581491 10.1016/0014-5793(89)80476-4 (Pubitemid 19020112)
79. Castell J. V., Gomes-Lechon M. J., David M., Hirano T., Kishimoto T., Heinrich P. C., Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Letters 1988 232 2 347 350 2-s2.0-0023887261 10.1016/0014-5793(88)80766-X
80. Koh K. K., Han S. H., Quon M. J., Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. Journal of the American College of Cardiology 2005 46 11 1978 1985 2-s2.0-28244466397 10.1016/j.jacc.2005.06.082 (Pubitemid 41713578)
81. Haught W. H., Mansour M., Rothlein R., Kishimoto T. K., Mainolfi E. A., Hendricks J. B., Hendricks C., Mehta J. L., Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. American Heart Journal 1996 132 1 I 1 8 2-s2.0-0029908639 10.1016/S0002-8703(96)90383-X (Pubitemid 26243685)
82. Laaksonen D. E., Niskanen L., Punnonen K., Nyyssönen K., Tuomainen T. P., Salonen R., Rauramaa R., Salonen J. T., Sex hormones, inflammation and the metabolic syndrome: a population-based study. European Journal of Endocrinology 2003 149 6 601 608 2-s2.0-0346728590 10.1530/eje.0.1490601 (Pubitemid 38054707)
83. Fernández-Real J. M., Ricart W., Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003 24 3 278 301 2-s2.0-0037631831 (Pubitemid 36724371)
84. Yudkin J. S., Stehouwer C. D. A., Emeis J. J., Coppack S. W., C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 4 972 978 2-s2.0-0032943709 (Pubitemid 29177345)
85. Festa A., D'Agostino R., Howard G., Mykkänen L., Tracy R. P., Haffner S. M., Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000 101 1 42 47 2-s2.0-0034604248 (Pubitemid 30430551)
86. Han T. S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M. E. J., Haffner S. M., Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care 2002 25 11 2016 2021 2-s2.0-0036833814 10.2337/diacare.25. 11.2016 (Pubitemid 41071061)
87. Ridker P. M., Buring J. E., Cook N. R., Rifai N., C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003 107 3 391 397 2-s2.0-0037469255
88. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D. S. J., Haffner S. M., Isles C., Macfarlane P. W., Packard C. J., Cobbe S. M., Shepherd J., Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 108 4 414 419 2-s2.0-0042665536 10.1161/01.CIR. 0000080897.52664.94 (Pubitemid 36935533)
89. Williams D. E. M., Prevost A. T., Whichelow M. J., Cox B. D., Day N. E., Wareham N. J., A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. British Journal of Nutrition 2000 83 3 257 266 2-s2.0-0034048888 (Pubitemid 30125221)
90. McKeown N. M., Meigs J. B., Liu S., Saltzman E., Wilson P. W. F., Jacques P. F., Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004 27 2 538 546 2-s2.0-0842333082 10.2337/diacare.27.2.538 (Pubitemid 38174084)
91. Panagiotakos D. B., Pitsavos C., Chrysohoou C., Skoumas J., Tousoulis D., Toutouza M., Toutouzas P., Stefanadis C., Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. American Heart Journal 2004 147 1 106 112 2-s2.0-0347416930 10.1016/S0002- 8703(03)00442-3 (Pubitemid 38037405)
92. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., D'Armiento M., D'Andrea F., Giugliano D., Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Journal of the American Medical Association 2004 292 12 1440 1446 2-s2.0-4544288392 10.1001/jama.292.12.1440 (Pubitemid 39258336)
93. Ahluwalia N., Andreeva V. A., Kesse-Guyot E., Hercberg S., Dietary patterns, inflammation and the metabolic syndrome. Diabetes & Metabolism 2012 10.1016/j.diabet.2012.08.007
94. Lazich I., Sarafidis P., de Guzman E., Patel A., Oliva R., Bakris G., Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes, Obesity and Metabolism 2012 14 2 181 186 10.1111/j.1463-1326.2011.01510.x
95. Devaraj S., Chan E., Jialal I., Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 11 4489 4496 2-s2.0-33751519338 10.1210/jc.2006-0299 (Pubitemid 44833428)
96. Ridker P. M., Rifai N., Rose L., Buring J. E., Cook N. R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England Journal of Medicine 2002 347 20 1557 1565 2-s2.0-0037078969 10.1056/NEJMoa021993 (Pubitemid 35315836)
97. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 1997 336 14 973 979 2-s2.0-0030956673 10.1056/NEJM199704033361401 (Pubitemid 27152782)
98. Tracy R. P., Lemaitre R. N., Psaty B. M., Ives D. G., Evans R. W., Cushman M., Meilahn E. N., Kuller L. H., Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 6 1121 1127 2-s2.0-0030979827 (Pubitemid 27260332)
99. Koenig W., Sund M., Fröhlich M., Fischer H. G., Löwel H., Döring A., Hutchinson W. L., Pepys M. B., C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999 99 2 237 242 2-s2.0-0032923669 (Pubitemid 29056365)
100. Cesari M., Penninx B. W. J. H., Newman A. B., Kritchevsky S. B., Nicklas B. J., Sutton-Tyrrell K., Rubin S. M., Ding J., Simonsick E. M., Harris T. B., Pahor M., Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation 2003 108 19 2317 2322 2-s2.0-0242610488 10.1161/01.CIR.0000097109.90783.FC (Pubitemid 37413536)
101. Ridker P. M., Rifai N., Stampfer M. J., Hennekens C. H., Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000 101 15 1767 1772 2-s2.0-0034681920 (Pubitemid 30213096)
102. Ridker P. M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E., Elevation of tumor necrosis factor- α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000 101 18 2149 2153 2-s2.0-0034625079 (Pubitemid 30253042)
103. Lau D. C. W., Dhillon B., Yan H., Szmitko P. E., Verma S., Adipokines: molecular links between obesity and atheroslcerosis. American Journal of Physiology 2005 288 5 H2031 H2041 2-s2.0-18044366410 10.1152/ajpheart.01058.2004 (Pubitemid 40604084)
104. Ridker P. M., Hennekens C. H., Buring J. E., Rifai N., C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England Journal of Medicine 2000 342 12 836 843 2-s2.0-0034704893 10.1056/NEJM200003233421202 (Pubitemid 30165206)
105. Kuller L. H., Eichner J. E., Orchard T. J., Grandits G. A., McCallum L., Tracy R. P., The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial. American Journal of Epidemiology 1991 134 11 1266 1277 2-s2.0-0026331584
106. Liuzzo G., Biasucci L. M., Gallimore J. R., Grillo R. L., Rebuzzi A. G., Pepys M. B., Maseri A., The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. The New England Journal of Medicine 1994 331 7 417 424 2-s2.0-0027933081 10.1056/NEJM199408183310701 (Pubitemid 24247397)
107. Thompson S. G., Kienast J., Pyke S. D. M., Haverkate F., Van de Loo J. C. W., Luscher E. F., Boissel J. P., Brakman P., Julian D. G., Prentice C. R. M., Verstraete M., Haverkate F., Bricaud H., Duckert F., Hugenholtz P. G., Lubsen J., Muller U. S., Breithardt G., Brochier M., Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. The New England Journal of Medicine 1995 332 10 635 641 2-s2.0-0028909230 10.1056/NEJM199503093321003
108. Ridker P. M., Rifai N., Pfeffer M. A., Sacks F. M., Moye L. A., Goldman S., Flaker G. C., Braunwald E., Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 98 9 839 844 2-s2.0-0032169240 (Pubitemid 28397432)
109. Ridker P. M., Glynn R. J., Hennekens C. H., C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998 97 20 2007 2011 2-s2.0-0032568486 (Pubitemid 28243661)
110. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J. R., Pepys M. B., Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. British Medical Journal 2000 321 7255 199 204 2-s2.0-0034702485 (Pubitemid 30459555)
111. Albert C. M., Ma J., Rifai N., Stampfer M. J., Ridker P. M., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 105 22 2595 2599 2-s2.0-0037024228 10.1161/01.CIR.0000017493.03108.1C (Pubitemid 34596034)
112. Kuller L. H., Tracy R. P., Shaten J., Meilahn E. N., Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. American Journal of Epidemiology 1996 144 6 537 547 2-s2.0-0029810933 (Pubitemid 26304398)
113. Mendall M. A., Strachan D. P., Butland B. K., Ballam L., Morris J., Sweetnam P. M., Elwood P. C., C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. European Heart Journal 2000 21 19 1584 1590 2-s2.0-0033799673 10.1053/euhj.1999.1982
114. Harris T. B., Ferrucci L., Tracy R. P., Corti M. C., Wacholder S., Ettinger W. H., Heimovitz H., Cohen H. J., Wallace R., Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine 1999 106 5 506 512 2-s2.0-0033134682 10.1016/S0002-9343(99)00066-2 (Pubitemid 29231100)
115. Roberts W. L., CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: laboratory tests available to asses inflammation-performance and standardization: a background paper. Circulation 2004 110 25 e572 e576 2-s2.0-21344464359
116. Bisoendial R. J., Boekholdt S. M., Vergeer M., Stroes E. S. G., Kastelein J. J. P., C-reactive protein is a mediator of cardiovascular disease. European Heart Journal 2010 31 17 2087 2091 2-s2.0-77956398698
117. Wilson P. W., Pencina M., Jacques P., Selhub J., D'Agostino R., O'Donnell C. J., C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circulation 2008 1 2 92 97 2-s2.0-59649121465
118. Keavney B., C reactive protein and the risk of cardiovascular disease. British Medical Journal 2011 342, article d144 2-s2.0-79953034778 10.1136/bmj.d144
119. Fortmann S. P., Ford E., Criqui M. H., Folsom A. R., Harris T. B., Hong Y., Pearson T. A., Siscovick D., Vinicor F., Wilson P. F., CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group. Circulation 2004 110 25 e554 e559 2-s2.0-28744455066
120. de Lorgeril M., Salen P., Martin J. L., Monjaud I., Delaye J., Mamelle N., Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999 99 6 779 785 2-s2.0-0032955055 (Pubitemid 29083018)
121. Singh R. B., Dubnov G., Niaz M. A., Ghosh S., Singh R., Rastogi S. S., Manor O., Pella D., Berry E. M., Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. The Lancet 2002 360 9344 1455 1461 2-s2.0-0037048928 10.1016/S0140-6736(02)11472-3 (Pubitemid 35356323)
122. Pischon T., Hankinson S. E., Hotamisligil G. S., Rifai N., Willett W. C., Rimm E. B., Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003 108 2 155 160 2-s2.0-0038447923 10.1161/01.CIR.0000079224.46084.C2 (Pubitemid 36871296)
123. Djoussé L., Pankow J. S., Eckfeldt J. H., Folsom A. R., Hopkins P. N., Province M. A., Hong Y., Ellison R. C., Relation between dietary linolenic acid and coronary artery disease in the National Heart, Lung, and Blood Institute Family Heart study. American Journal of Clinical Nutrition 2001 74 5 612 619 2-s2.0-0034748162 (Pubitemid 33015147)
124. Lopez-Garcia E., Schulze M. B., Manson J. E., Meigs J. B., Albert C. M., Rifai N., Willett W. C., Hu F. B., Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. Journal of Nutrition 2004 134 7 1806 1811 2-s2.0-3042786322 (Pubitemid 38886573)
125. Madsen T., Skou H. A., Hansen V. E., Fog L., Christensen J. H., Toft E., Schmidt E. B., C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. American Journal of Cardiology 2001 88 10 1139 1142 2-s2.0-0035889484 10.1016/S0002-9149(01)02049-5 (Pubitemid 33043846)
126. Zhao G., Etherton T. D., Martin K. R., West S. G., Gillies P. J., Kris-Etherton P. M., Dietary α -linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. Journal of Nutrition 2004 134 11 2991 2997 2-s2.0-7944228499 (Pubitemid 39470074)
127. Rallidis L. S., Paschos G., Liakos G. K., Velissaridou A. H., Anastasiadis G., Zampelas A., Dietary α -linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 2003 167 2 237 242 2-s2.0-0038463560 10.1016/S0021-9150(02) 00427-6 (Pubitemid 36773523)
128. Bemelmans W. J. E., Lefrandt J. D., Feskens E. J. M., van Haelst P. L., Broer J., Meyboom-de Jong B., May J. F., Cohen Tervaert J. W., Smit A. J., Increased α -linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition 2004 58 7 1083 1089 2-s2.0-4043114874 10.1038/sj.ejcn.1601938 (Pubitemid 39077156)
129. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
130. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., Macfarlane P. W., Mckillop J. H., Packard C. J., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The New England Journal of Medicine 1995 333 20 1301 1307 2-s2.0-0028883828 10.1056/NEJM199511163332001
131. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Journal of the American Medical Association 1998 279 20 1615 1622 2-s2.0-0032572086 10.1001/jama.279.20.1615 (Pubitemid 28248586)
132. Ridker P. M., Cannon C. P., Morrow D., Rifai N., Rose L. M., McCabe C. H., Pfeffer M. A., Braunwald E., C-reactive protein levels and outcomes after statin therapy. The New England Journal of Medicine 2005 352 1 20 28 2-s2.0-11344279659 10.1056/NEJMoa042378 (Pubitemid 40075677)
133. Morrow D. A., de Lemos J. A., Sabatine M. S., Wiviott S. D., Blazing M. A., Shui A., Rifai N., Califf R. M., Braunwald E., Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006 114 4 281 288 2-s2.0-33748064338 10.1161/CIRCULATIONAHA.106.628909 (Pubitemid 44297094)
134. Nissen S. E., Tuzcu E. M., Schoenhagen P., Crowe T., Sasiela W. J., Tsai J., Orazem J., Magorien R. D., O'Shaughnessy C., Ganz P., Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England Journal of Medicine 2005 352 1 29 38 2-s2.0-19944429519 10.1056/NEJMoa042000 (Pubitemid 40075678)
135. Ridker P. M., Danielson E., Fonseca F. A., Genest J., Gotto A. M., Kastelein J. J., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 2009 373 9670 1175 1182 2-s2.0-63649095045 10.1016/S0140-6736(09)60447-5
136. Liao J. K., Role of statin pleiotropism in acute coronary syndromes and stroke. International Journal of Clinical Practice, Supplement 2003 134 51 57 2-s2.0-0038327836 (Pubitemid 36565036)
137. Rosenson R. S., Tangney C. C., Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Journal of the American Medical Association 1998 279 20 1643 1650 2-s2.0-0032572043 10.1001/jama.279.20.1643 (Pubitemid 28248591)
138. Li J. J., Chen X. J., Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coronary Artery Disease 2003 14 4 329 334 2-s2.0-0041365914 10.1097/00019501-200306000- 00009 (Pubitemid 36900662)
139. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A., Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. International Journal of Cardiology 2001 77 2-3 247 253 2-s2.0-0035138445 10.1016/S0167-5273(00)00439-3 (Pubitemid 32155911)
140. Wæhre T., Damås J. K., Gullestad L., Holm A. M., Pedersen T. R., Arnesen K. E., Torsvik H., Frøland S. S., Semb A. G., Aukrust P., Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Journal of the American College of Cardiology 2003 41 9 1460 1467 2-s2.0-0038747064 10.1016/S0735-1097(03)00263-8 (Pubitemid 36543360)
141. Wæhre T., Yndestad A., Smith C., Haug T., Tunheim S. H., Gullestad L., Frøland S. S., Semb A. G., Aukrust P., Damås J. K., Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004 109 16 1966 1972 2-s2.0-11144355152 10.1161/01.CIR.0000125700.33637.B1 (Pubitemid 38544487)
142. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 3 327 334 2-s2.0-0035908632 (Pubitemid 32656163)
143. Festa A., D'Agostino R. Jr., Tracy R. P., Haffner S. M., Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002 51 4 1131 1137 2-s2.0-0036230414 (Pubitemid 34438360)
144. Nakanishi S., Yamane K., Kamei N., Okubo M., Kohno N., Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003 26 10 2754 2757 2-s2.0-0141446219 10.2337/diacare.26.10.2754 (Pubitemid 37205542)
145. Tan K. C. B., Wat N. M. S., Tam S. C. F., Janus E. D., Lam T. H., Lam K. S. L., C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care 2003 26 8 2323 2328 2-s2.0-0042524670 10.2337/diacare.26.8.2323 (Pubitemid 36993320)
146. Thorand B., Löwel H., Schneider A., Kolb H., Meisinger C., Fröhlich M., Koenig W., C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg Cohort Study, 1984-1998. Archives of Internal Medicine 2003 163 1 93 99 2-s2.0-0037434058 10.1001/archinte.163.1.93 (Pubitemid 36091606)
147. Barzilay J. I., Abraham L., Heckbert S. R., Cushman M., Kuller L. H., Resnick H. E., Tracy R. P., The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001 50 10 2384 2389 2-s2.0-0035488931 (Pubitemid 33641926)
148. Freeman D. J., Norrie J., Caslake M. J., Gaw A., Ford I., Lowe G. D. O., O'Reilly D. S. J., Packard C. J., Sattar N., C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. Diabetes 2002 51 5 1596 1600 2-s2.0-0036312978 (Pubitemid 34826630)
149. Snijder M. B., Dekker J. M., Visser M., Stehouwer C. D. A., van Hinsberg V. W. M., Bouter L. M., Heine R. J., C-reactive protein and diabetes mellitus type 2. Diabetologia 2001 44 Supplement 1, article 115A
150. Senn J. J., Klover P. J., Nowak I. A., Zimmers T. A., Koniaris L. G., Furlanetto R. W., Mooney R. A., Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. The Journal of Biological Chemistry 2003 278 16 13740 13746 2-s2.0-0037853260 10.1074/jbc.M210689200 (Pubitemid 36799910)
151. Pickup J. C., Crook M. A., Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998 41 10 1241 1248 2-s2.0-0031720795 10.1007/s001250051058 (Pubitemid 28449093)
152. Lagrand W. K., Visser C. A., Hermens W. T., Niessen H. W. M., Verheugt F. W. A., Wolbink G. J., Hack C. E., C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation 1999 100 1 96 102 2-s2.0-0033529379 (Pubitemid 29297946)
153. Sakkinen P. A., Wahl P., Cushman M., Lewis M. R., Tracy R. P., Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology 2000 152 10 897 907 2-s2.0-0034669480 10.1093/aje/152.10.897
154. Hak A. E., Pols H. A. P., Stehouwer C. D. A., Meijer J., Kiliaan A. J., Hofman A., Breteler M. M. B., Witteman J. C. M., Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study. Journal of Clinical Endocrinology and Metabolism 2001 86 9 4398 4405 2-s2.0-0034855391 10.1210/jc.86.9.4398 (Pubitemid 32848565)
155. Temelkova-Kurktschiev T., Siegert G., Bergmann S., Henkel E., Koehler C., Jaroß W., Hanefeld M., Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002 51 6 743 749 2-s2.0-0036278738 10.1053/meta.2002.32804 (Pubitemid 34624841)
156. Müller S., Martin S., Koenig W., Hanifi-Moghaddam P., Rathmann W., Haastert B., Giani G., Illig T., Thorand B., Kolb H., Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002 45 6 805 812 2-s2.0-18744414292
157. Temelkova-Kurktschiev T., Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002 45 1, article 151 2-s2.0-18244366670 10.1007/s125-002-8256-1 (Pubitemid 34118556)
158. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M., Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. The Journal of Clinical Investigation 1995 95 5 2409 2415 2-s2.0-0028931724
159. Saghizadeh M., Ong J. M., Garvey W. T., Henry R. R., Kern P. A., The expression of TNF α by human muscle: relationship to insulin resistance. The Journal of Clinical Investigation 1996 97 4 1111 1116 2-s2.0-0030028606 (Pubitemid 26070591)
160. Peraldi P., Spiegelman B., TNF- α and insulin resistance: summary and future prospects. Molecular and Cellular Biochemistry 1998 182 1-2 169 175 2-s2.0-0031892271 10.1023/A:1006865715292 (Pubitemid 28181660)
161. Katsuki A., Sumida Y., Murashima S., Murata K., Takarada Y., Ito K., Fujii M., Tsuchihashi K., Goto H., Nakatani K., Yano Y., Serum levels of tumor necrosis factor- α are increased in obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1998 83 3 859 862 2-s2.0-15644362064 10.1210/jc.83.3.859 (Pubitemid 28496458)
162. Winkler G., Salamon F., Salamon D., Speer G., Simon K., Cseh K., Elevated serum tumour necrosis factor. alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 1998 41 7 860 862 2-s2.0-0031838312 10.1007/s001250051000 (Pubitemid 28313723)
163. Pickup J. C., Chusney G. D., Thomas S. M., Burt D., Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sciences 2000 67 3 291 300 2-s2.0-0034625547 10.1016/S0024- 3205(00)00622-6 (Pubitemid 30413937)
164. Vozarova B., Weyer C., Lindsay R. S., Pratley R. E., Bogardus C., Tataranni P. A., High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002 51 2 455 461 2-s2.0-0036066485 (Pubitemid 34764803)
165. Steel D. M., Whitehead A. S., The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today 1994 15 2 81 87 2-s2.0-0027952502 10.1016/0167-5699(94)90138-4 (Pubitemid 24049801)
166. Steinberg G. R., Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 2007 6 8 888 894 2-s2.0-34247489726 (Pubitemid 46658739)
167. Kim F., Tysseling K. A., Rice J., Pham M., Haji L., Gallis B. M., Baas A. S., Paramsothy P., Giachelli C. M., Corson M. A., Raines E. W., Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKK β Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 5 989 994 2-s2.0-20944436777 10.1161/01.ATV.0000160549.60980.a8 (Pubitemid 40627844)
168. Roden M., Price T. B., Perseghin G., Petersen K. F., Rothman D. L., Cline G. W., Shulman G. I., Mechanism of free fatty acid-induced insulin resistance in humans. The Journal of Clinical Investigation 1996 97 12 2859 2865 2-s2.0-0029948212 (Pubitemid 26197099)
169. Shoelson S. E., Lee J., Yuan M., Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. International Journal of Obesity and Related Metabolic Disorders 2003 27 Supplement 3 S49 S52 (Pubitemid 38019189)
170. Hotamisligil G. S., Inflammatory pathways and insulin action. International Journal of Obesity 2003 27 3 S53 S55 2-s2.0-0346880504 10.1038/sj.ijo.0802502 (Pubitemid 38019190)
171. Cai D., Yuan M., Frantz D. F., Melendez P. A., Hansen L., Lee J., Shoelson S. E., Local and systemic insulin resistance resulting from hepatic activation of IKK- β and NF- B. Nature Medicine 2005 11 2 183 190 2-s2.0-14644427890 10.1038/nm1166 (Pubitemid 40321354)
172. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance. The Journal of Clinical Investigation 2006 116 7 1793 1801 2-s2.0-33745861300 10.1172/JCI29069
173. Bruno G., Fornengo P., Novelli G., Panero F., Perotto M., Segre O., Zucco C., Deambrogio P., Bargero G., Perin P. C., C-reactive protein and 5-year survival in type 2 diabetes: the casale monferrato study. Diabetes 2009 58 4 926 933 2-s2.0-64649099304 10.2337/db08-0900
174. Wellen K. E., Hotamisligil G. S., Inflammation, stress, and diabetes. The Journal of Clinical Investigation 2005 115 5 1111 1119 2-s2.0-18244370762 10.1172/JCI200525102 (Pubitemid 40629025)
175. Kaneto H., Nakatani Y., Miyatsuka T., Kawamori D., Matsuoka T. A., Matsuhisa M., Kajimoto Y., Ichijo H., Yamasaki Y., Hori M., Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nature Medicine 2004 10 10 1128 1132 2-s2.0-7044230885 10.1038/nm1111 (Pubitemid 39424876)
176. Liu G., Rondinone C. M., JNK: bridging the insulin signaling and inflammatory pathway. Current Opinion in Investigational Drugs 2005 6 10 979 987 2-s2.0-27544487938 (Pubitemid 41535781)
177. Maeda K., Cao H., Kono K., Gorgun C. Z., Furuhashi M., Uysal K. T., Cao Q., Atsumi G., Malone H., Krishnan B., Minokoshi Y., Kahn B. B., Parker R. A., Hotamisligil G. S., Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism 2005 1 2 107 119 2-s2.0-18244363982 10.1016/j.cmet.2004.12.008 (Pubitemid 43960591)
178. Hundal R. S., Petersen K. F., Mayerson A. B., Randhawa P. S., Inzucchi S., Shoelson S. E., Shulman G. I., Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. The Journal of Clinical Investigation 2002 109 10 1321 1326 2-s2.0-0036099857 10.1172/JCI200214955 (Pubitemid 34546896)
179. Goldfine A. B., Silver R., Aldhahi W., Cai D., Tatro E., Lee J., Shoelson S. E., Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and Translational Science 2008 1 1 36 43 2-s2.0-64149121817 10.1111/j.1752-8062.2008.00026.x
180. Goldfine A. B., Fonseca V., Jablonski K. A., Pyle L., Staten M. A., Shoelson S. E., The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Annals of Internal Medicine 2010 152 6 346 357 2-s2.0-77950885686
181. Fleischman A., Shoelson S. E., Bernier R., Goldfine A. B., Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008 31 2 289 294 2-s2.0-38949119419 10.2337/dc07-1338 (Pubitemid 351213338)
182. Koska J., Ortega E., Bunt J. C., Gasser A., Impson J., Hanson R. L., Forbes J., de Courten B., Krakoff J., The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009 52 3 385 393 2-s2.0-59449090513 10.1007/s00125-008-1239-x
183. Sathyapalan T., Shepherd J., Atkin S. L., Kilpatrick E. S., The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes, Obesity and Metabolism 2013 10.1111/dom.12074
184. Cummings D. M., King D. E., Mainous A. G. III, C-reactive protein, antiinflammatory drugs, and quality of life in diabetes. Annals of Pharmacotherapy 2003 37 11 1593 1597 2-s2.0-0142182460 10.1345/aph.1D029 (Pubitemid 37315096)
185. Rabkin S. W., Langer A., Ur E., Calciu C. D., Leiter L. A., Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy. Hypertension Research 2013 10.1038/hr.2012.214
186. Wägner A. M., Sánchez-Quesada J. L., Benítez S., Bancells C., Ordóñez-Llanos J., Pérez A., Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Research and Clinical Practice 2011 93 1 e25 e28 10.1016/j.diabres.2011.03.009
187. Colbert J. D., Stone J. A., Statin use and the risk of incident diabetes mellitus: a review of the literature. Canadian Journal of Cardiology 2012 28 5 581 589 10.1016/j.cjca.2012.03.021